Skip to main content

Advancing the standard of care in plastic surgery

Plastic surgery patient care extends beyond the operating room. While confidence in the OR is essential, postoperative concerns like infections, swelling and tissue integration can impact recovery. 3M™ Prevena™ Therapy provides you with a proactive strategy for incision care, elevating the standard of postoperative treatment and optimizing the healing environment to enhance your patients' recovery experience. 

Contact a representative
Applying 3M™ Prevena Restor™ Bella Form™ dressing to double masectomy patient. MedPeople_OR_13762
Impact of Prevena Therapy Proactive Risk Management Videos Resources Contact us
On this page...
Impact of Prevena Therapy
Proactive Risk Management
Videos
Resources
Contact us

Enhanced plastic surgery outcomes with Prevena Therapy

A peer-reviewed meta-analysis of 16 studies for various plastic surgery procedures demonstrated 3M™ Prevena™ Therapy helped significantly reduce the risk of various surgical site complications (SSCs) while helping to improve health economic outcomes compared to standard-of-care dressings.1

Reduction in SSIs1,*

11 studies; p<0.001†

reduction in dehiscence1,*,** 

9 studies; p=0.001†

† Calculation(s) are derived based on the relative patient group incidence rate reporting in this study. Statistically significant (p<0.05).
*Relative risk reduction
**The use of Prevena Therapy for the reduction in the incidence of dehiscence has not been reviewed by the U.S. FDA.

The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at https://eifu.solventum.com/.

Prevena Therapy video resources 

Contact a Solventum representative

We're here to help! Our team of representatives can provide you with information and resources to help you. Submit the form below to speak with a Solventum representative to learn more about your options.

Looking for customer support? Visit the customer support page.

Fields marked with an * are required.

 

Solventum will use the information to respond to your request in accordance with our Privacy Policy. 

NOTE:

Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

Indication(s) For Use / Intended Use: US FDA Cleared: Only for Use in the United States:

Prevena Dressing used with Prevena Therapy Units: PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible PREVENA™ dressings for up to seven days, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma; and in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

Limitations:

  • The device is not intended to treat surgical site infection or seroma.
  • Safety and effectiveness in pediatric population (<22 years old) have not been evaluated.
  • Safety and effectiveness in Class III (Contaminated) and Class IV (Dirty/Infected) wounds have not been demonstrated. Furthermore, Class IV surgical wounds are not expected to be closed primarily, and the subject device should only be used on closed surgical incisions.
  • The device has not been demonstrated to reduce deep incisional and organ space surgical site infections.
  • The device has not been demonstrated to be effective in reducing the incidence of surgical site infection and seroma in all surgical procedures and patient populations; therefore, the device may not be recommended for routine use to reduce the incidence of surgical site infection and seroma.
  • Please refer to the ‘Summary of Clinical Information’ section for the specific surgical procedures and patient populations included in the clinical studies. Surgeons should continue to follow the ‘Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection’2 and the ‘American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines’3 for best practices in preventing surgical site infection. US FDA Cleared: Dressings/ Systems (Prevena Dressings used with compatible Solventum NPWT units - ActiVAC, Ulta, and RX4) and applicable OUS countries that leverage US Indication: The PREVENA™, PREVENA PLUS™, PREVENA DUO™, and PREVENA RESTOR™ Incision Management Systems are intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy.

References:

  1. Gabriel A, Singh D, Silverman RP, Collinsworth A, Bongards C, Griffin L. ePlasty. 2023 Mar 31;23:e22. Closed incision negative pressure therapy versus standard of care over closed plastic surgery incisions in the reduction of surgical site complications: A systematic review and meta-analysis of comparative studies
  2. Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D. W., Leas, B., Stone, E. C., Kelz, R. R., Reinke, C. E., Morgan, S., Solomkin, J. S., Mazuski, J. E., Dellinger, E. P., Itani, K. M., Berbari, E. F., Segreti, J., Parvizi, J., Blanchard, J., Allen, G., Kluytmans, J. A., Donlan, R., & Schecter, W. P. (2017). Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surgery, 152(8), 784. https://doi.org/10.1001/jamasurg.2017.0904
  3. Ban, K. A., Minei, J. P., Laronga, C., Harbrecht, B. G., Jensen, E. H., Fry, D. E., Itani, K. M. F., Dellinger, P. E., Ko, C. Y., & Duane, T. M. (2017). American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 update. Journal of the American College of Surgeons, 224(1), 59–74. https://doi.org/10.1016/j.jamcollsurg.2016.10.029